Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 14, 2014; 20(38): 13999-14003
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13999
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13999
Small intestinal bacterial overgrowth in inactive Crohn’s disease: Influence of thiopurine and biological treatment
Cristina Sánchez-Montes, Vicente Ortiz, Guillermo Bastida, Ester Rodríguez, María Yago, Belén Beltrán, Mariam Aguas, Marisa Iborra, Vicente Garrigues, Julio Ponce, Pilar Nos, Gastroenterology Unit, Hospital Universitari i Politécnic La Fe, 46026 Valencia, Spain
Author contributions: All authors contributed equally to the research design, conducting the research, analysis, data interpretation, drafting the paper, and approving the final version of the article.
Correspondence to: Cristina Sánchez-Montes, Physician, Gastroenterology Unit, Hospital Universitari i Politécnic La Fe, Bulevar Sur s/n, 46026 Valencia, Spain. sanchez_cri@gva.es
Telephone: +34-961-245859 Fax: +34-961-246257
Received: October 25, 2013
Revised: January 15, 2014
Accepted: May 29, 2014
Published online: October 14, 2014
Processing time: 232 Days and 12.7 Hours
Revised: January 15, 2014
Accepted: May 29, 2014
Published online: October 14, 2014
Processing time: 232 Days and 12.7 Hours
Core Tip
Core tip: Thiopurine Immunosuppressants and biological drugs used in Crohn’s disease are not free from side effects, such as acquiring infections. Our study demonstrated no association between drug treatment and bacterial overgrowth. These results may be explained as the treatment promoting better disease control.